Gsk annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gsk Stock-Based Compensation Growth & History (GSK)
Gsk's stock-based compensation was £390.0M for fiscal 2025.
View full Gsk company overviewGsk annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £390.0M | £43.0M | +12.39% |
| 2024 | 2024-12-31 | £347.0M | £26.0M | +8.10% |
| 2023 | 2023-12-31 | £321.0M | £7.0M | +2.23% |
| 2022 | 2022-12-31 | £314.0M | −£31.0M | −8.99% |
| 2021 | 2021-12-31 | £345.0M | £15.0M | +4.55% |
| 2020 | 2020-12-31 | £330.0M | −£102.0M | −23.61% |
| 2019 | 2019-12-31 | £432.0M | £39.0M | +9.92% |
| 2018 | 2018-12-31 | £393.0M | £46.0M | +13.26% |
| 2017 | 2017-12-31 | £347.0M | £9.0M | +2.66% |
| 2016 | 2016-12-31 | £338.0M | −£11.0M | −3.15% |
| 2015 | 2015-12-31 | £349.0M | — | — |
Gsk stock-based compensation trends
Over the last five fiscal years, Gsk's stock-based compensation increased from £330.0M to £390.0M, a change of £60.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gsk source filings ↗